Ahmad R Alsayed, Luai Hasoun, Heba A Khader, Mahmoud S Abu-Samak, Laith Mh Al-Shdifat, Basheer Al-Shammari, Mohammed Al Maqbali
{"title":"新冠肺炎患者与非典型细菌的共同感染：约旦的一项研究。","authors":"Ahmad R Alsayed, Luai Hasoun, Heba A Khader, Mahmoud S Abu-Samak, Laith Mh Al-Shdifat, Basheer Al-Shammari, Mohammed Al Maqbali","doi":"10.18549/PharmPract.2023.1.2753","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The aim of this work was to know the prevalence of <i>Chlamydophila pneumoniae</i> and <i>Mycoplasma pneumoniae</i> in coronavirus disease 2019 (COVID-19) patients in Jordan. Also, to assess a TaqMan real-time polymerase chain reaction (PCR) assay in detecting these two bacteria.</p><p><strong>Methods: </strong>This is a retrospective study performed over the last five months of the 2021. All nasopharyngeal specimens from COVID-19 patients were tested for C. pneumonia, and M. pneumoniae. The <i>C. pneumoniae</i> Pst-1 gene and <i>M. pneumoniae</i> P1 cytadhesin protein gene were the targets.</p><p><strong>Results: </strong>In this study, 14 out of 175 individuals with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (8.0%) were co-infected with <i>C. pneumoniae</i> or <i>M. pneumoniae</i>. Co-infection with SARS-CoV-2 and <i>C. pneumoniae</i> was reported in 5 (2.9%) patients, while 9 (5.1%) patients had <i>M. pneumoniae</i> and SARS-CoV-2 co-infection. The mean (± std) of the correlation coefficient of the calibration curve for real-time PCR analysis was -0.993 (± 0.001) for <i>C. pneumoniae</i> and -0.994 (± 0.003) for <i>M. pneumoniae</i>. The mean amplification efficiencies of <i>C. pneumoniae</i> and <i>M. Pneumoniae</i> were 187.62% and 136.86%, respectively.</p><p><strong>Conclusion: </strong>In this first study based in Jordan, patients infected with COVID-19 have a low rate of atypical bacterial co-infection. However, clinicians should suspect co-infections with both common and uncommon bacteria in COVID-19 patients. Large prospective investigations are needed to give additional insight on the true prevalence of these co-infections and their impact on the clinical course of COVID-19 patients.</p>","PeriodicalId":51762,"journal":{"name":"Pharmacy Practice-Granada","volume":"21 1","pages":"2753"},"PeriodicalIF":2.4000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ae/0f/pharmpract-21-2753.PMC10117357.pdf","citationCount":"4","resultStr":"{\"title\":\"Co-infection of COVID-19 patients with atypical bacteria: A study based in Jordan.\",\"authors\":\"Ahmad R Alsayed, Luai Hasoun, Heba A Khader, Mahmoud S Abu-Samak, Laith Mh Al-Shdifat, Basheer Al-Shammari, Mohammed Al Maqbali\",\"doi\":\"10.18549/PharmPract.2023.1.2753\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>The aim of this work was to know the prevalence of <i>Chlamydophila pneumoniae</i> and <i>Mycoplasma pneumoniae</i> in coronavirus disease 2019 (COVID-19) patients in Jordan. Also, to assess a TaqMan real-time polymerase chain reaction (PCR) assay in detecting these two bacteria.</p><p><strong>Methods: </strong>This is a retrospective study performed over the last five months of the 2021. All nasopharyngeal specimens from COVID-19 patients were tested for C. pneumonia, and M. pneumoniae. The <i>C. pneumoniae</i> Pst-1 gene and <i>M. pneumoniae</i> P1 cytadhesin protein gene were the targets.</p><p><strong>Results: </strong>In this study, 14 out of 175 individuals with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (8.0%) were co-infected with <i>C. pneumoniae</i> or <i>M. pneumoniae</i>. Co-infection with SARS-CoV-2 and <i>C. pneumoniae</i> was reported in 5 (2.9%) patients, while 9 (5.1%) patients had <i>M. pneumoniae</i> and SARS-CoV-2 co-infection. The mean (± std) of the correlation coefficient of the calibration curve for real-time PCR analysis was -0.993 (± 0.001) for <i>C. pneumoniae</i> and -0.994 (± 0.003) for <i>M. pneumoniae</i>. The mean amplification efficiencies of <i>C. pneumoniae</i> and <i>M. Pneumoniae</i> were 187.62% and 136.86%, respectively.</p><p><strong>Conclusion: </strong>In this first study based in Jordan, patients infected with COVID-19 have a low rate of atypical bacterial co-infection. However, clinicians should suspect co-infections with both common and uncommon bacteria in COVID-19 patients. Large prospective investigations are needed to give additional insight on the true prevalence of these co-infections and their impact on the clinical course of COVID-19 patients.</p>\",\"PeriodicalId\":51762,\"journal\":{\"name\":\"Pharmacy Practice-Granada\",\"volume\":\"21 1\",\"pages\":\"2753\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ae/0f/pharmpract-21-2753.PMC10117357.pdf\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmacy Practice-Granada\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.18549/PharmPract.2023.1.2753\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/11/9 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacy Practice-Granada","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18549/PharmPract.2023.1.2753","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/11/9 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Co-infection of COVID-19 patients with atypical bacteria: A study based in Jordan.
Objective: The aim of this work was to know the prevalence of Chlamydophila pneumoniae and Mycoplasma pneumoniae in coronavirus disease 2019 (COVID-19) patients in Jordan. Also, to assess a TaqMan real-time polymerase chain reaction (PCR) assay in detecting these two bacteria.
Methods: This is a retrospective study performed over the last five months of the 2021. All nasopharyngeal specimens from COVID-19 patients were tested for C. pneumonia, and M. pneumoniae. The C. pneumoniae Pst-1 gene and M. pneumoniae P1 cytadhesin protein gene were the targets.
Results: In this study, 14 out of 175 individuals with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (8.0%) were co-infected with C. pneumoniae or M. pneumoniae. Co-infection with SARS-CoV-2 and C. pneumoniae was reported in 5 (2.9%) patients, while 9 (5.1%) patients had M. pneumoniae and SARS-CoV-2 co-infection. The mean (± std) of the correlation coefficient of the calibration curve for real-time PCR analysis was -0.993 (± 0.001) for C. pneumoniae and -0.994 (± 0.003) for M. pneumoniae. The mean amplification efficiencies of C. pneumoniae and M. Pneumoniae were 187.62% and 136.86%, respectively.
Conclusion: In this first study based in Jordan, patients infected with COVID-19 have a low rate of atypical bacterial co-infection. However, clinicians should suspect co-infections with both common and uncommon bacteria in COVID-19 patients. Large prospective investigations are needed to give additional insight on the true prevalence of these co-infections and their impact on the clinical course of COVID-19 patients.
期刊介绍：
Pharmacy Practice is a free full-text peer-reviewed journal with a scope on pharmacy practice. Pharmacy Practice is published quarterly. Pharmacy Practice does not charge and will never charge any publication fee or article processing charge (APC) to the authors. The current and future absence of any article processing charges (APCs) is signed in the MoU with the Center for Pharmacy Practice Innovation (CPPI) at Virginia Commonwealth University (VCU) School of Pharmacy. Pharmacy Practice is the consequence of the efforts of a number of colleagues from different Universities who belief in collaborative publishing: no one pays, no one receives. Although focusing on the practice of pharmacy, Pharmacy Practice covers a wide range of pharmacy activities, among them and not being comprehensive, clinical pharmacy, pharmaceutical care, social pharmacy, pharmacy education, process and outcome research, health promotion and education, health informatics, pharmacoepidemiology, etc.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
